Genomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1  Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be treated with approved targeted therapy drugs, and more (such as MET, RET, and exon 20 insertions) have clinical trial options.1  Patients and caregivers dealing with…